Research Current study
Now openThe Hidden Readiness Gap
From AI Activity to Decision Advantage in the Life Sciences
Help identify what enables life science organizations, including pharmaceutical, biotech, medical device and equipment, and life science tools companies, to turn AI activity into better decisions and reliable value.
- Time
- About 8 to 10 minutes
- Format
- 19 core questions, online
- Participation
- Voluntary and confidential
From AI activity to decision advantage
Many organizations can point to AI pilots and tools. Fewer can show that AI has changed a consequential decision. This study looks at the organizational conditions that make the difference.
Decision impact
Where AI has changed important decisions or ways of working, whether that impact is measured, and what most limits its value.
Data fit
Whether the data behind priority AI initiatives is documented, traceable and fit for its intended use, whether it is created internally or sourced externally.
Governance and accountability
How clearly organizations can define what AI is approved to do, who is accountable for the outcome and where responsibility would break down after an error.
Human oversight
When human judgment is built into AI-enabled workflows, and how organizations decide what AI can do independently and where people must review or decide.
Workforce and roles
How far roles, incentives and career paths have been updated for AI-enabled work.
External partner readiness
How ready the CROs, CDMOs, labs, data partners and technology providers that AI initiatives depend on are to support them.
Investment discipline
Whether investment approvals account for the full cost of making AI, data, lab and automation investments work.
Leadership blind spots
The AI risks senior leaders most often underestimate, and the challenges they are not yet discussing clearly enough.
For this survey, AI includes predictive analytics, machine learning, generative AI and AI-enabled automation.
Who should take part
Primary participants
Senior leaders who own strategy, portfolio, investment or operating decisions in life science organizations.
Seniority
Associate Vice President (AVP) level or above, including Vice Presidents, Senior and Executive Vice Presidents, and C-suite executives.
Organizations
Pharmaceutical, biotech, medical device and equipment, and life science tools companies.
Equivalent titles
Leaders with a different title who carry equivalent responsibility, such as the global head of a function, are included as well.
Functions
- Therapeutic area, franchise and portfolio strategy
- R&D, clinical development and clinical operations
- Regulatory affairs, safety and pharmacovigilance
- Medical affairs, real-world evidence and HEOR
- Manufacturing, CMC and quality
- Commercial, market access, launch and patient strategy
- Business development, licensing and corporate strategy
Other perspectives
Everyone else working in a life science or healthcare organization is welcome, at any level and in any function, including the digital, data and technology leaders who make AI work in practice. These responses are analyzed separately from the primary group and add an important view of how AI decisions are carried out.
Exclusive insight for the leaders who take part
These materials are for primary participants only, as described above.
A proprietary blind-spot check for leadership teams
A framework built from the study themes that shows where your AI plans may be exposed, so you can act before gaps become costly. Shared in the weeks after you take part.
Your results, benchmarked against your peers
Your own responses alongside the aggregated results, so you can see how your views compare with other industry leaders. You also receive an executive brief on what the research shows before the findings are published.
A private executive roundtable
The option to express interest in an exclusive, invitation-only roundtable in Boston for executive leaders to discuss study outcomes and exchange ideas. Seats are limited.
Responses from other perspectives are just as valuable to the study, but are not eligible for these materials. Materials are sent to the email you give in the survey. Receiving them does not subscribe you to Talon Catalyst or any other marketing. The Study Privacy Notice explains how your information is used and protected, including in comparison reports.
Your responses are confidential.
- We collect your name, company, role and email alongside your answers for research and study administration.
- Published findings will not identify you or your company without your permission.
- Sharing your name, company and job title is expected. Please do not include patient information, trade secrets or confidential details about your organization's products, plans or data.
- Participation does not subscribe you to marketing or authorize sales outreach. It does not require a newsletter subscription, a sales conversation or a LinkedIn connection.
- Read the Study Privacy Notice for how we collect, use and protect your information, and the choices you have.
Questions about the study
For questions about the study, corrections to your responses or withdrawal, email info@talongroup.consulting. Your rights and choices are set out in the Study Privacy Notice.
Help build the evidence base
Your perspective helps show what separates AI activity from decision advantage across the life sciences.
